corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 17303

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Comer B
Prescriber data law in Maine headed for federal court
Medical Marketing & Media 2010 Feb 25
http://www.mmm-online.com/prescriber-data-law-in-maine-headed-for-federal-court/article/164522/


Full text:

A federal appeals court will hear oral arguments regarding Maine’s prescription data law, which allows physicians to “opt-out” of commercially traded data pertaining to their prescribing habits.

The Prescription Restraint Law in Maine was first passed in 2007 and scheduled to take effect in January 2008, but was halted by a preliminary injunction awarded by District Court Judge John Woodcock. Marketing research firms involved in the case – including IMS Health, SDI and Source Analytics – hope the federal appeals court will be sympathetic to a First Amendment argument against the law.

“As a general matter, the setting of a case for oral argument means that the appeals court has reviewed the briefs filed by all parties and has concluded that they raise significant issues that should be explored further,” said Cathy Betz, VP government affairs at MR firm Wolters Kluwer Pharma Solutions.

Betz said that the preliminary injunction freezing the law was modified January 1, 2008, to allow doctors in Maine to sign up in advance for the law’s opt-out provision in the event that the injunction is terminated. To finance this sign-up period, the state of Maine rolled out a $1,500 annual fee on all pharmaceutical manufacturers dispensing drugs in the state. “Many [pharmas] received invoices from [Maine] in October for $1,500 or more, and had no idea what it was for,” said Betz. As of September 2009, 249 doctors had signed up to opt-out, she said.

The 1st Circuit Court of Appeals will hear oral arguments April 5, 2010. The same court reinstated a stricter prescription data ban in New Hampshire, after a district court overturned the original law. The Supreme Court refused last summer to weigh in on that decision, so market researchers in Maine will have their work cut out for them.

IMS Health posted a “Fact versus Fiction” checklist on its website, listing prominent arguments for state-level data bans, and the company’s rejoinders. Free speech is impeded in Maine, despite the opt-out clause of the law, according to IMS Health’s checklist.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.